Dual-Targeting CAR t therapy takes on Hard-to-Treat myeloma

NCT ID NCT05850234

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Apr 07, 2026 · Last updated May 16, 2026 · Updated 6 times

Summary

This study tests a new treatment called AZD0120 for people with multiple myeloma that has returned or stopped responding to at least three prior therapies. The treatment uses a patient's own immune cells, which are modified in a lab to recognize and attack two targets (CD19 and BCMA) on myeloma cells. The goal is to see if this therapy is safe and effective at shrinking or controlling the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
RECRUITING

Birmingham, Alabama, 35233, United States
Research Site
RECRUITING

Phoenix, Arizona, 85054, United States
Research Site
RECRUITING

La Jolla, California, 92037, United States
Research Site
RECRUITING

Los Angeles, California, 90095, United States
Research Site
RECRUITING

San Francisco, California, 94143, United States
Research Site
RECRUITING

Aurora, Colorado, 80045, United States
Research Site
RECRUITING

Denver, Colorado, 80218, United States
Research Site
RECRUITING

Jacksonville, Florida, 32224, United States
Research Site
NOT_YET_RECRUITING

Miami, Florida, 33136, United States
Research Site
RECRUITING

Tampa, Florida, 33612, United States
Research Site
RECRUITING

Atlanta, Georgia, 30322, United States
Research Site
RECRUITING

Chicago, Illinois, 60637, United States
Research Site
RECRUITING

Iowa City, Iowa, 52242, United States
Research Site
RECRUITING

Boston, Massachusetts, 02114, United States
Research Site
RECRUITING

Boston, Massachusetts, 02215, United States
Research Site
RECRUITING

Ann Arbor, Michigan, 48109, United States
Research Site
RECRUITING

Detroit, Michigan, 48202, United States
Research Site
NOT_YET_RECRUITING

Minneapolis, Minnesota, 55455, United States
Research Site
RECRUITING

Rochester, Minnesota, 55905, United States
Research Site
WITHDRAWN

Omaha, Nebraska, 68198, United States
Research Site
WITHDRAWN

Hackensack, New Jersey, 07601, United States
Research Site
NOT_YET_RECRUITING

Buffalo, New York, 14203, United States
Research Site
RECRUITING

New York, New York, 10065, United States
Research Site
RECRUITING

Stony Brook, New York, 11794, United States
Research Site
RECRUITING

Charlotte, North Carolina, 28204, United States
Research Site
RECRUITING

Durham, North Carolina, 27705, United States
Research Site
RECRUITING

Nashville, Tennessee, 37203, United States
Research Site
RECRUITING

Nashville, Tennessee, 37232, United States
Research Site
RECRUITING

Austin, Texas, 78704, United States
Research Site
RECRUITING

Dallas, Texas, 75390, United States
Research Site
RECRUITING

Houston, Texas, 77030, United States
Research Site
NOT_YET_RECRUITING

Salt Lake City, Utah, 84112, United States
Research Site
RECRUITING

Charlottesville, Virginia, 22908, United States
Research Site
RECRUITING

Edmonds, Washington, 98026, United States
Research Site
RECRUITING

Seattle, Washington, 98109, United States
Research Site
RECRUITING

Milwaukee, Wisconsin, 53226, United States

Conditions

Explore the condition pages connected to this study.

RELAPSED/REFRACTORY MULTIPLE MYELOMA